Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression

Vista senzilla d'ítem
dc.contributor.authorBragado, Paloma
dc.contributor.authorFernández-Nogueira, Patricia
dc.contributor.authorCarbó Carbó, Neus
dc.contributor.authorGascón, Pere
dc.date.accessioned2021-03-30T14:53:29Z
dc.date.available2021-03-30T14:53:29Z
dc.date.issued2020-12-08
dc.date.updated2021-03-30T14:53:29Z
dc.description.abstractThe majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].
dc.format.extent3 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec710528
dc.identifier.issn1949-2553
dc.identifier.pmid33346249
dc.identifier.urihttps://hdl.handle.net/2445/175915
dc.language.isoeng
dc.publisherImpact Journals
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.27829
dc.relation.ispartofOncotarget, 2020, vol. 11, num. 49, p. 4541-4543
dc.relation.urihttps://doi.org/10.18632/oncotarget.27829
dc.rightscc-by (c) Bragado, Paloma et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationFibroblasts
dc.subject.classificationCàncer
dc.subject.otherFibroblasts
dc.subject.otherCancer
dc.titleUnraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
710528.pdf
Mida:
1.11 MB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Bioquímica i Biomedicina Molecular)